BCL2 and acute myeloid leukemia: Inhibition of MAPK/ERK and MDM2 exhibits synergistic effects in AML that are dependent on upregulation of PUMA (p53 up-regulated modulator of apoptosis, alternatively BBC3) and BIM (BCL-2 interacting mediator of cell death, alternatively BCL2L11) [153].